Michigan Business & Entrepreneurial Law Review
Menu
  • Home
  • About MBELR
    • Current Editorial Board
    • Past Boards
      • Volume 11
      • Volume 10
      • Volume 9
      • Volume 8
      • Volume 7
      • Volume 6
      • Volume 5
      • Volume 4
      • Volume 3
      • Volume 2
      • Volume 1
    • Subscribe
    • Submit Work
  • Print
    • Current Issue
    • Archive
  • MBELR Blog
    • Blog Posts
      • Vol. 14 Blog Posts
      • Vol. 13 Blog Posts
      • Vol. 12 Blog Posts
Menu

Author: Avni J. Patel

Pharmaceutical Pricing: The Free Market and Government Regulation on Drug Companies

Posted on December 1, 2015 by Avni J. Patel

Since Martin Shkreli announced that he would lower the price of Daraprim by an unnamed amount at some point in the future; as of this writing, he has not done so.1 Critics of Shkreli claim that the announcement to lower the price was merely a tactic to placate critics.2 Shkreli has responded by stating that such…

Pharmaceutical Pricing: The Intersection of Big Business and Healthcare

Posted on October 13, 2015 by Avni J. Patel

Until recently, Daraprim was a little known name.1 That is, until Turing Pharmaceuticals acquired the drug in August and increased the price of the drug from $13.50 to $750 per pill.2 Daraprim, known generically as pyrimethamine, is used mainly to “treat toxoplasmosis, a parasite infection that can cause serious or even life-threatening problems for babies…

© 2025 Michigan Business & Entrepreneurial Law Review | Powered by Minimalist Blog WordPress Theme